Other targeted therapies with VEGFR antibodies (aflibercept, ramucirumab) and tyrosine kinase inhibitors with selectivity for VEGFRs (sorafenib, sunitinib, nintedanib, cediranib, motesanib, pazopanib, axitinib, vandetanib) showed responses and improved PFS but no survival advantages in patients with advanced NSCLC [4]. The gene discussed is KDR; the disease is non-small cell lung carcinoma.